Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON55251
NL-OMON55251
Completed
Not Applicable

An exploratory study of durvalumab (MEDI4736) uptake during concurrent chemoradiotherapy in stage III NSCLC patients using 89Zr-labeled durvalumab PET - CONDOR

Vrije Universiteit Medisch Centrum0 sites10 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionslung cancerlung carcinoma1003866610029107

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
lung cancer
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
10
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\* Have a histologically or cytologically confirmed diagnosis of thoracic
  • •disease stage III NSCLC and planned to receive concurrent chemotherapy and
  • •radiotherapy on the thorax.
  • •\* Patients with oligometastatic stage IV comprising a thoracic stage III and up
  • •to 2 distant metastases amenable for radical local consolidative therapy are
  • •also eligible.
  • •\* Capable of giving signed informed consent which includes compliance with the
  • •requirements and restrictions listed in the informed consent form (ICF) and in
  • •this protocol.
  • •\* Written informed consent obtained from the subject prior to performing any

Exclusion Criteria

  • •\* Concurrent enrolment in another clinical study, unless it is an observational
  • •(non\-interventional) clinical study, or during the follow\-up period of an
  • •interventional study.
  • •\* Participation in another clinical study with an investigational product
  • •during the last 4 weeks.
  • •\* Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy,
  • •endocrine therapy, targeted therapy, biologic therapy, tumor embolization,
  • •monoclonal antibodies) \* 30 days prior to the first dose of study drug If
  • •sufficient wash\-out time has not occurred due to the schedule or PK properties
  • •of an agent, a longer wash\-out period will be required, as agreed by

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Does immunotherapy (durvalumab) accumulate in the tumors of patients with lung cancer receiving chemotherapy together with radiotherapy.
EUCTR2019-004284-51-NLAmsterdam UMC, VU University Medical Center10
Active, not recruiting
Phase 1
Treatment of patients with HIV-1 and advanced solid tumors with Durvalumabadvanced solid tumors in HIV-1 infected patientsTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-004524-38-ESSpanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón)20
Suspended
Phase 1
A phase Ib study of durvalumab (MEDI4736) tremelimumab combined with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasio
JPRN-jRCT2031210046Ogasawara Sadahisa15
Active, not recruiting
Phase 1
A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-003998-17-BEGrand Hôpital de Charleroi57
Recruiting
Not Applicable
Phase II, single-arm study of durvalumab (MEDI4736) and AZD 6738 combination therapy in relapsed small cell lung cancer Subjects
KCT0005058Samsung Medical Center45